{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-039903","form_type":"8-K","ticker":"CRMD","cik":"0001410098","company_name":"CorMedix Inc.","filed_at":"2025-05-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.200080+00:00","generated_at":"2026-05-22T11:23:23.950161+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"CorMedix Q1 2025 net revenue $39.1M, net income $20.6M vs loss; raises H1 guidance to high-end","bullets":["Q1 net revenue $39.1M; net income $20.6M ($0.32 EPS) vs net loss of $14.5M ($0.25 loss) in Q1 2024.","Adjusted EBITDA $23.6M; cash from operations $19.7M; cash and short-term investments $77.5M at March 31.","Expects to be at high-end of H1 2025 net sales guidance of $62M-$70M based on current order trends.","Inpatient sales team fully staffed; DefenCath inpatient shipments doubled in last 3 months; Phase 3 TPN-CLABSI study started."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-039903","json":"https://secwatch.observer/filing/0001213900-25-039903.json","markdown":"https://secwatch.observer/filing/0001213900-25-039903.md","text":"https://secwatch.observer/filing/0001213900-25-039903.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1410098/000121390025039903/0001213900-25-039903-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1410098/000121390025039903/ea0240827-8k_cormedix.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T11:23:23.950161+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}